Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EBT (2016 - 2025)

BioCorRx's EBT history spans 15 years, with the latest figure at -$808505.0 for Q3 2025.

  • For Q3 2025, EBT rose 46.56% year-over-year to -$808505.0; the TTM value through Sep 2025 reached -$4.3 million, up 13.91%, while the annual FY2024 figure was -$5.2 million, 38.23% down from the prior year.
  • EBT for Q3 2025 was -$808505.0 at BioCorRx, up from -$1.4 million in the prior quarter.
  • Across five years, EBT topped out at -$808505.0 in Q3 2025 and bottomed at -$1.6 million in Q1 2021.
  • The 5-year median for EBT is -$1.2 million (2022), against an average of -$1.1 million.
  • The largest annual shift saw EBT tumbled 74.44% in 2024 before it surged 46.56% in 2025.
  • A 5-year view of EBT shows it stood at -$1.2 million in 2021, then rose by 3.0% to -$1.2 million in 2022, then rose by 16.9% to -$969943.0 in 2023, then decreased by 26.57% to -$1.2 million in 2024, then skyrocketed by 34.14% to -$808505.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's EBT are -$808505.0 (Q3 2025), -$1.4 million (Q2 2025), and -$851764.0 (Q1 2025).